<DOC>
	<DOCNO>NCT00820950</DOCNO>
	<brief_summary>The study comprise two part . The first portion study double-blind , Sponsor-unblinded , vehicle-controlled study application INCB018424 vehicle pair lesion least 15 cm apart patient active stable plaque psoriasis . Part 2 study double-blind , sponsor unblinded , comparison INCB018424 two FDA approve product patient active stable plaque psoriasis .</brief_summary>
	<brief_title>A Study INCB018424 Phosphate Cream When Applied Patients With Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Body Mass Index ( BMI ) 17 40 kg/m2 Subjects must two comparable psoriatic lesion measure 9 100 cm2 target lesion must similar size , separate least 15 cm . Subjects lesions solely involve palm hand sol foot intertriginous area , scalp face . Subjects pustular psoriasis erythroderma . Subjects currently topical agent UVB therapy within 2 week first dose study medication . Subjects receive PUVA within 4 week first dose study medication . Subjects receive systemic retinoids , etanercept , adalimumab efalizumab oral immunosuppressive within 3 month prior first dose study medication . Subjects receive biological therapy ( infliximab , alefacept , abatacept , etc ) within 3 month first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>